Analysis on the infection among patients with nephrotic syndromes and systemic vasculitis treated with mycophenolate mofetil.

摘要

As a new type of immune suppressant which inhibits the proliferation of T and B lymphocytes as well as antibody production by B cells, mycophenolate mofetil (MMF) has achieved not only notable therapeutic effects against graft rejection but also significant improvements in the treatment of autoimmune diseases and kidney diseases in recent years [1-3], providing a new treatment of refractory glomerular diseases [4-6]. Current studies demonstrate that MMF has a lower incidence of adverse events compared with conventional immune suppressants [7-9]. However, in our clinical practices, we observed that infection is still among the major MMF-related adverse events and may result in severe outcomes under certain circumstances. We analyze the incidence and etiology in a group of patients with glomerular diseases and systemic vasculitis receiving long-term MMF therapv.